Evidence map›Paper›PMID 39670006›Full record

ArticleTranslational lung cancer research2024

Nanao Terada, Hayato Koba, Shigeki Nanjo, Hideharu Kimura, Akihiro Nishiyama, Taro Yoneda, Takayuki Takeda, Hiroki Shirasaki, Koichi Nishi, Takashi Sone and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. ConcurrentJournal of thoracic disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Nanao Terada *Department of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.ORCID https://orcid.org/0000-0002-3055-7737
Hayato Koba *Department of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Shigeki Nanjo *Department of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Hideharu KimuraDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Akihiro NishiyamaDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Taro YonedaDepartment of Respiratory Medicine, Komatsu Municipal Hospital, Komatsu, Japan.
Takayuki TakedaDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Hiroki ShirasakiDepartment of Respiratory Medicine, Fukui-ken Saiseikai Hospital, Fukui, Japan.
Koichi NishiDepartment of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Takashi SoneDepartment of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Tadaaki YamadaDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Koichi TakayamaDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kazuhiko ShibataDepartment of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Japan.
Hiroki MatsuokaDepartment of Internal Medicine, Keiju Medical Center, Nanao, Japan.
Toshiyuki KitaDepartment of Respiratory Medicine, National Hospital Organization, Kanazawa Medical Center, Kanazawa, Japan.
Kazuhiro NagataDepartment of Internal Medicine, Koseikai Takeda Hospital, Kyoto, Japan.
Yuichi TamboDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Noriyuki OhkuraDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Johsuke HaraDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Kazuo KasaharaDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Shinji KohsakaDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Seiji YanoDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is widely used as a first-line treatment for Methods: This study was conducted as a prospective clinical trial in patients with Results: Paired specimens were obtained before and at the time of resistance to afatinib treatment, and specimens only at afatinib resistance were obtained from 22 and 18 patients, respectively. In plasma cfDNA from the 22 cases, driver Conclusions: These results suggested that V834L cooperates with other coexisting mutations to influence the therapeutic efficacy of EGFR-TKIs.

Indexed as

cell-free DNA (cfDNA)Co-mutationepidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)liquid biopsyresistance

Identifiers

PMID39670006
PMCPMC11632430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.